Carbon footprint impact of the choice of inhalers for asthma and COPD

In the 1990s, metered dose inhalers (MDIs) containing chlorofluorocarbons were replaced with dry-powder inhalers (DPIs) and MDIs containing hydrofluorocarbons (HFCs). While HFCs are not ozone depleting, they are potent greenhouse gases. Annual carbon footprint (CO(2)e), per patient were 17 kg for Re...

Descripción completa

Detalles Bibliográficos
Autores principales: Janson, Christer, Henderson, Richard, Löfdahl, Magnus, Hedberg, Martin, Sharma, Raj, Wilkinson, Alexander J K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929707/
https://www.ncbi.nlm.nih.gov/pubmed/31699805
http://dx.doi.org/10.1136/thoraxjnl-2019-213744
Descripción
Sumario:In the 1990s, metered dose inhalers (MDIs) containing chlorofluorocarbons were replaced with dry-powder inhalers (DPIs) and MDIs containing hydrofluorocarbons (HFCs). While HFCs are not ozone depleting, they are potent greenhouse gases. Annual carbon footprint (CO(2)e), per patient were 17 kg for Relvar-Ellipta/Ventolin-Accuhaler; and 439 kg for Seretide-Evohaler/Ventolin-Evohaler. In 2017, 70% of all inhalers sold in England were MDI, versus 13% in Sweden. Applying the Swedish DPI and MDI distribution to England would result in an annual reduction of 550 kt CO(2)e. The lower carbon footprint of DPIs should be considered alongside other factors when choosing inhalation devices.

Ejemplares similares